• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

万古霉素在腹膜炎患者持续性不卧床腹膜透析中的药代动力学。

Vancomycin pharmacokinetics during continuous ambulatory peritoneal dialysis in patients with peritonitis.

机构信息

Pharmacy Service, El Pinar Nurse Home Hospital, Avd/Ferrandis Salvador No. 46, 12100 Castellón, Spain.

出版信息

Eur J Pharm Sci. 2011 Jul 17;43(4):212-6. doi: 10.1016/j.ejps.2011.04.006. Epub 2011 Apr 20.

DOI:10.1016/j.ejps.2011.04.006
PMID:21540106
Abstract

The aim of this study was to define a two-compartments pharmacokinetic model and to estimate the pharmacokinetic parameters of IP administered vancomycin in patients with continuous ambulatory peritoneal dialysis (CAPD) associated peritonitis. Ten patients with peritoneal dialysis treatment and peritonitis were prospectively enrolled in the study. The empiric treatment is: vancomycin 2 g every 5-7 days and ceftazidime 1500 mg per exchange, once daily. Pharmacokinetic modeling and parameter calculations were carried out using the nonlinear regression. The mean peritoneal concentration 10 min after the first peritoneal exchange of vancomycin free dialysis liquid was 9.5±7.3 μg/ml, showing that antibiotic quickly crosses from "systemic" to "peritoneal" compartment. Then, we can appreciate a progressive reduction in the mean peritoneal concentration till last sample time at 168 h. The mean plasma concentration 4 h after the first peritoneal exchange of vancomycin-free dialysis liquid was 39.6±7.6 μg/ml, inside classic interval therapeutic range for the peak concentration of vancomycin. Then, we can appreciate a progressive reduction in the mean plasma concentration till last sample time at 168 h. Simultaneous joint analysis of the experimental plasma and peritoneal data of vancomycin in patients under CAPD with peritonitis, using the two-compartments model, sets up a physiologic model that adapts suitably to the intraperitoneal pharmacotherapy.

摘要

本研究旨在确定一个双室药代动力学模型,并估计腹膜透析(CAPD)相关性腹膜炎患者中 IP 给予万古霉素的药代动力学参数。10 例腹膜透析治疗合并腹膜炎的患者前瞻性纳入本研究。经验性治疗为:万古霉素 2 g 每 5-7 天 1 次,头孢他啶 1500 mg 每袋 1 次,每天 1 次。使用非线性回归进行药代动力学建模和参数计算。首次腹膜交换万古霉素无透析液后 10 分钟的平均腹膜浓度为 9.5±7.3 μg/ml,表明抗生素迅速从“全身”向“腹膜”室转移。然后,我们可以看到平均腹膜浓度逐渐降低,直到 168 小时的最后一个样本时间。首次腹膜交换万古霉素无透析液后 4 小时的平均血浆浓度为 39.6±7.6 μg/ml,处于万古霉素峰浓度的经典治疗范围内。然后,我们可以看到平均血浆浓度逐渐降低,直到 168 小时的最后一个样本时间。同时分析 CAPD 相关性腹膜炎患者的实验性血浆和腹膜万古霉素数据,使用双室模型,建立了一个适合腹腔内药物治疗的生理模型。

相似文献

1
Vancomycin pharmacokinetics during continuous ambulatory peritoneal dialysis in patients with peritonitis.万古霉素在腹膜炎患者持续性不卧床腹膜透析中的药代动力学。
Eur J Pharm Sci. 2011 Jul 17;43(4):212-6. doi: 10.1016/j.ejps.2011.04.006. Epub 2011 Apr 20.
2
[Monitoring of intraperitoneal administration of vancomycin in patients on continuous ambulatory peritoneal dialysis].[持续性非卧床腹膜透析患者腹腔内注射万古霉素的监测]
Farm Hosp. 2012 Sep-Oct;36(5):328-35. doi: 10.1016/j.farma.2011.03.009. Epub 2012 Jan 20.
3
Treatment of peritoneal dialysis-associated peritonitis with continuous versus intermittent vancomycin/teicoplanin and ceftazidime in children: preliminary results of a prospective randomized trial. Members of APN Arbeitsgemeinschaft Paidiatrische Nephrologie.儿童腹膜透析相关性腹膜炎连续与间歇应用万古霉素/替考拉宁及头孢他啶治疗:一项前瞻性随机试验的初步结果。APN儿科肾脏病工作小组成员。
Adv Perit Dial. 1995;11:296-301.
4
Efficacy and safety of meropenem plus tobramycin followed by meropenem plus vancomycin for treating peritonitis in patients on continuous ambulatory peritoneal dialysis.美罗培南联合妥布霉素继以美罗培南联合万古霉素治疗持续性非卧床腹膜透析患者腹膜炎的疗效及安全性
Adv Perit Dial. 2006;22:65-8.
5
Vancomycin therapy for treatment of peritonitis in outpatients on peritoneal dialysis.
Hiroshima J Med Sci. 1998 Sep;47(3):105-7.
6
Disposition of ceftazidime after intraperitoneal administration in adolescent patients receiving continuous cycling peritoneal dialysis.接受持续循环腹膜透析的青少年患者腹腔内给予头孢他啶后的处置情况。
Am J Kidney Dis. 2006 Mar;47(3):503-8. doi: 10.1053/j.ajkd.2005.11.010.
7
Intraperitoneal vancomycin and ceftazidime in the treatment of CAPD peritonitis.腹腔内注射万古霉素和头孢他啶治疗持续性非卧床腹膜透析相关性腹膜炎
Clin Nephrol. 1985 Feb;23(2):81-4.
8
Use of bolus intraperitoneal aminoglycosides for treating peritonitis in end-stage renal disease patients receiving continuous ambulatory peritoneal dialysis and continuous cycling peritoneal dialysis.在接受持续性非卧床腹膜透析和持续性循环腹膜透析的终末期肾病患者中,使用大剂量腹腔内氨基糖苷类药物治疗腹膜炎。
Adv Perit Dial. 2000;16:280-4.
9
[Treatment of peritonitis under continuous ambulatory peritoneal dialysis using intraperitoneal ceftazidime].[持续非卧床腹膜透析时腹腔内使用头孢他啶治疗腹膜炎]
Pathol Biol (Paris). 1989 Jun;37(5 Pt 2):681-4.
10
Single UK centre experience on the treatment of PD peritonitis--antibiotic levels and outcomes.英国单中心关于腹膜透析相关性腹膜炎治疗的经验——抗生素水平与治疗结果
Nephrol Dial Transplant. 2007 Jun;22(6):1714-9. doi: 10.1093/ndt/gfm079. Epub 2007 Mar 17.

引用本文的文献

1
Pharmacokinetic analysis of ceftazidime and cefazolin in the treatment of continuous ambulatory peritoneal dialysis-related peritonitis.头孢他啶和头孢唑林治疗持续性非卧床腹膜透析相关性腹膜炎的药代动力学分析。
Ren Fail. 2023;45(2):2285873. doi: 10.1080/0886022X.2023.2285873. Epub 2023 Dec 4.
2
Dose Tailoring of Vancomycin Through Population Pharmacokinetic Modeling Among Surgical Patients in Pakistan.通过群体药代动力学模型对巴基斯坦外科患者进行万古霉素剂量调整
Front Pharmacol. 2021 Nov 11;12:721819. doi: 10.3389/fphar.2021.721819. eCollection 2021.
3
Vancomycin in peritoneal dialysis: Clinical pharmacology considerations in therapy.
万古霉素在腹膜透析中的应用:治疗中的临床药理学考虑。
Perit Dial Int. 2020 Jul;40(4):384-393. doi: 10.1177/0896860819889774. Epub 2020 Feb 17.
4
Vancomycin therapeutic drug monitoring and population pharmacokinetic models in special patient subpopulations.万古霉素治疗药物监测及特殊患者亚人群的群体药代动力学模型。
Pharmacol Res Perspect. 2018 Jul;6(4):e00420. doi: 10.1002/prp2.420.
5
Vancomycin: the tale of the vanquisher and the pyrrhic victory.万古霉素:征服者的故事与惨胜
Perit Dial Int. 2014 Mar-Apr;34(2):154-61. doi: 10.3747/pdi.2014.00001.